PASADENA, Calif.-(BUSINESS WIRE)---- Sarwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis's United States Patent No. 9,593,333 ("the '333 patent† ) is invalid and not infringed by Arrowhead's planned commercialization of investigational plozasiran, which is under FDA review. Arrowhead intends to vigorously. ...

临床管线进展 - 未来6至9个月内将推进MAPT进入临床阶段 成为首款通过皮下注射给药的中枢神经系统药物 [2] - 随后将推进首款二聚体药物PCSK9 APOC3进入临床 该药物针对动脉粥样硬化性心血管疾病具有潜在强大疗效 [2] 关键监管里程碑 - 11月将迎来plozasiran的PDUFA审评日期 标志着公司从纯研发型向研发商业化一体化转型的关键节点 [3] 临床数据发布计划 - 年内发布INHBE和ALK7在肥胖症领域的临床数据 [3] - 2026年上半年追加发布更多ALK7相关数据 该数据较INHBE给药时间线延迟约6个月 [3]